Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.27)
# 2,576
Out of 4,712 analysts
26
Total ratings
45.45%
Success rate
-0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.33 | +157.51% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $620.16 | +13.84% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $124.09 | +37.00% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $21.09 | +208.20% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.59 | +335.73% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $156.50 | +31.63% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $42.04 | +56.99% | 2 | Aug 8, 2024 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $2.48 | +787.10% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $3.66 | +173.22% | 1 | May 30, 2023 | |
| ABBV AbbVie | Maintains: Outperform | $159 → $165 | $179.44 | -8.05% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $15.25 | +293.44% | 1 | Oct 5, 2022 |
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.33
Upside: +157.51%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $620.16
Upside: +13.84%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $124.09
Upside: +37.00%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $21.09
Upside: +208.20%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.59
Upside: +335.73%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $156.50
Upside: +31.63%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $42.04
Upside: +56.99%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.48
Upside: +787.10%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $3.66
Upside: +173.22%
AbbVie
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $179.44
Upside: -8.05%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $15.25
Upside: +293.44%